Triple negative breast cancer
RecruitingStudy of Atezolizumab, Vinorelbine, and Cyclophosphamide for Patients with Advanced Triple Negative Breast Cancer Previously Treated with Anti-PD-L1/PD-1
Study of Atezolizumab, Vinorelbine, and Cyclophosphamide for Patients with Advanced Triple Negative Breast Cancer Previously Treated with Anti-PD-L1/PD-1
- Disease:Triple negative breast cancer
- Substances:AtezolizumabVinorelbine+1
Italy- Participants:18–64 years · 65+ years
- Substances:Atezolizumab
- Sponsor:Istituto Europeo Di Oncologia S.r.l.









